English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe article, titled “Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms,” is the first to make an explicit comparison of academic and commercial licenses. Licenses of biotechnologies from academic institutions provide a mechanism by which scientific discoveries made with government-funded research grants are transferred to companies to develop commercial products. These licenses provide financial returns to the public sector, which universities can use to support research or education, and enable industry to develop innovative products, create jobs, and generate economic growth.
“Our previous work has shown that the U.S. government invests more than a billion dollars for the early-stage basic or applied research underlying each innovative, first-in-class drug. Here, we examined how much of the profit from such products is returned to the public.” said Fred Ledley, Director of the Center for Integration of Science and Industry, and the senior author on this study. “The results suggest that the public sector is not getting the same returns that a company would expect from similar licenses.”
The Bentley University study compared the economic terms of 239 biotechnology licenses from academic institutions to biotechnology companies with 916 comparable licenses between commercial firms. Academic licenses had lower royalty rates (3% versus 8%), lower total payments (deal size) ($900 thousand versus $31 million), and lower payments before product launch (precommercial payments) ($1.1 million versus $25 million). While academic licenses, on average, involved products at less advanced stages of development than corporate licenses, differences in the stage of development accounted for less than half of the disparity between academic and corporate licenses. Considering differences in stage of development together with differences in research payments, co-development, co-commercialization, exclusivity, or grants of stock, academic licenses had royalty rates that were 3-3.6% lower than corporate licenses, deal sizes that were $11.4-$12.2 million lower than corporate licenses, and precommercial payments that were $7.6-$9.4 million lower than corporate licenses.
Prateet Shah was the lead author of this work along with Dr. Gregory Vaughan and Dr. Ledley. Mr. Shah conducted this research as an undergraduate researcher at Bentley University.
This analysis used the BioSciDB database provided by Mark Edwards and BioScience Advisors, now part of Evaluate Ltd.
This work was supported by a grant from the National Biomedical Research Foundation.
THE CENTER FOR INTEGRATION OF SCIENCE AND INDUSTRY at Bentley University focuses on advancing the translation of scientific discoveries to create public value. The Center is an environment for interdisciplinary scholarship spanning basic science, data analytics, business and public policy. For more information, visit www.bentley.edu/sciindustry and follow us on Twitter @sciindustry and LinkedIn.
BENTLEY UNIVERSITY is more than just one of the nation’s top business schools. It is a lifelong-learning community that creates successful leaders who make business a force for positive change. With a combination of business and the arts and sciences and a flexible, personalized approach to education, Bentley provides students with critical thinking and practical skills that prepare them to lead successful, rewarding careers. Founded in 1917, the university enrolls 4,100 undergraduate and 1,000 graduate and PhD students and is set on 163 acres in Waltham, Massachusetts, 10 miles west of Boston. For more information, visit bentley.edu. For more information, visit bentley.edu. Follow us on Twitter @BentleyU #BentleyUResearch.
